DZDavid X. Zhang

David X. Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David X. Zhang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • David D. Gutterman

    Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, USA

    10 shared publications
  • Yoshinori Nishijima

    Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, USA

    6 shared publications
  • David A. Wilcox

    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Children's Research Institute, Children's Wisconsin, Milwaukee, Wisconsin, USA

    5 shared publications
  • Natalya S. Zinkevich

    Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, USA

    5 shared publications
  • Xiaodong Zheng

    Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

    5 shared publications
  • Ankush Korishettar

    Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, USA

    4 shared publications

Latest Publications

  • Open Access

    An update on regulation of the polymodal TRPV4 channel by protein phosphorylation

    by Aravind Parthasarathy, David X. Zhang

    TRPV4 is a polymodal Ca2+-permeable cation channel activated by diverse stimuli via various pathways and has been one of the difficult membrane proteins to comprehend, like other TRP channels. However, a broad range of functions and pathological conditions associated with these channels continues to fascinate researchers to study them. One of the major regulatory pathways of these channels is through protein phosphorylation catalyzed by various kinases (e.g. PKC, PKA, SGK1, and Src kinase) in a stimulus-specific manner. Several sites of protein phosphorylation have been identified in both N- and C-terminal tails located in the cytosolic region of the channel. One critical phosphorylation-mediated regulatory pathway involves the C-terminal phosphorylation of Ser-824 residue, which has been implicated in activation/sensitization of the channel and its functioning in cells. Due to the lack of structural evidence on the N- and C-terminal tails (largely intrinsically disordered), it remains a challenge to understand the molecular mechanisms involved in their regulation of the TRPV4 channel. However, recent studies have provided new insights into the potential mechanisms of phosphorylation regulation of the channel and helped unravel the complexity of TRPV4 regulation pathways. This review provides an updated summary of the regulatory role of post-translational regulation through phosphorylation, the kinases and residues involved in phosphorylation of the TRPV4 channel. Furthermore, we discuss the importance and potential mechanisms of the C-terminal domain, harboring the Ser-824 residue, in the regulation of channel activation and proper functioning.

  • The role of NO, H2O2, and non-NO/H2O2 mechanisms in acetylcholine (ACh)-induced dilation of human arterioles in the absence and presence of coronary artery disease

    by Kostiantyn Drachuk, Yoshinori Nishijima, Aravind Parthasarathy, Yangjing Xie, Sneha Nagavally, Aprill Dawson, David D. Gutterman, David X. Zhang

    This study defines the mechanisms of vasodilation to acetylcholine (ACh) in arterioles from patients with and without coronary artery disease (CAD). Human adipose arterioles (HAA) dissected from discarded surgical samples were cannulated and pressurized at 60 mmHg for measurement of diameter changes by videomicroscopy. No difference in baseline dose response to ACh was observed between non-CAD and CAD patients. L-NAME, NO synthase inhibitor, reduced dilation in both groups but to a greater extent in non-CAD. Peg-CAT, H2O2 scavenger, attenuated response to ACh in non-CAD but not in CAD. Inhibition of NOX4 reduced dilation in non-CAD, whereas NOX2 inhibition attenuated dilation in CAD. The SOD mimetic tempol partially normalized the NO- and H2O2-dependent dilation in CAD arterioles. EPR spin trapping indicated that absolute NO signal after ACh + A-23187 stimulation was higher in non-CAD than in CAD arteries. Western blot analysis revealed higher expression of monomeric eNOS but lower expression of dimeric eNOS and phosphorylated eNOS at Ser-1177 in CAD arteries. Finally, we found higher mRNA and protein expression of NOX2 in CAD arteries. These results provide new evidence that in normal human arterioles, both NO and H2O2 significantly contribute to ACh dilation, with substantial involvement of NOX4 in the H2O2-mediated response. In CAD, the contribution of both NO and H2O2 is diminished, while an NO/H2O2-independent hyperpolarizing pathway becomes predominant. Mechanistically, the NOX4-to-NOX2 switch may play a key role in mediating the change of vasodilator mechanisms in human arterioles during CAD.


  • Open Access

    Phosphorylation of distal C-terminal residues promotes TRPV4 channel activation in response to arachidonic acid

    by Aravind Parthasarathy, Andriy Anishkin, Yangjing Xie, Kostiantyn Drachuk, Yoshinori Nishijma, Juan Fang, Sevasti B. Koukouritaki, David A. Wilcox, David X. Zhang


  • Top Cited Papers
    Open Access

    Structure of human TRPV4 in complex with GTPase RhoA

    by Kirill D. Nadezhdin, Irina A. Talyzina, Aravind Parthasarathy, Arthur Neuberger, David X. Zhang, Alexander I. Sobolevsky

    Transient receptor potential (TRP) channel TRPV4 is a polymodal cellular sensor that responds to moderate heat, cell swelling, shear stress, and small-molecule ligands. It is involved in thermogenesis, regulation of vascular tone, bone homeostasis, renal and pulmonary functions. TRPV4 is implicated in neuromuscular and skeletal disorders, pulmonary edema, and cancers, and represents an important drug target. The cytoskeletal remodeling GTPase RhoA has been shown to suppress TRPV4 activity. Here, we present a structure of the human TRPV4-RhoA complex that shows RhoA interaction with the membrane-facing surface of the TRPV4 ankyrin repeat domains. The contact interface reveals residues that are mutated in neuropathies, providing an insight into the disease pathogenesis. We also identify the binding sites of the TRPV4 agonist 4α-PDD and the inhibitor HC-067047 at the base of the S1-S4 bundle, and show that agonist binding leads to pore opening, while channel inhibition involves a π-to-α transition in the pore-forming helix S6. Our structures elucidate the interaction interface between hTRPV4 and RhoA, as well as residues at this interface that are involved in TRPV4 disease-causing mutations. They shed light on TRPV4 activation and inhibition and provide a template for the design of future therapeutics for treatment of TRPV4-related diseases.


  • Open Access

    Inhibiting NADPH Oxidases to Target Vascular and Other Pathologies: An Update on Recent Experimental and Clinical Studies

    by Anthony L. Sylvester, David X. Zhang, Sophia Ran, Natalya S. Zinkevich

    Reactive oxygen species (ROS) can be beneficial or harmful in health and disease. While low levels of ROS serve as signaling molecules to regulate vascular tone and the growth and proliferation of endothelial cells, elevated levels of ROS contribute to numerous pathologies, such as endothelial dysfunctions, colon cancer, and fibrosis. ROS and their cellular sources have been extensively studied as potential targets for clinical intervention. Whereas various ROS sources are important for different pathologies, four NADPH oxidases (NOX1, NOX2, NOX4, and NOX5) play a prominent role in homeostasis and disease. NOX1-generated ROS have been implicated in hypertension, suggesting that inhibition of NOX1 may be a promising therapeutic approach. NOX2 and NOX4 oxidases are of specific interest due to their role in producing extra- and intracellular hydrogen peroxide (H2O2). NOX4-released hydrogen peroxide activates NOX2, which in turn stimulates the release of mitochondrial ROS resulting in ROS-induced ROS release (RIRR) signaling. Increased ROS production from NOX5 contributes to atherosclerosis. This review aims to summarize recent findings on NOX enzymes and clinical trials inhibiting NADPH oxidases to target pathologies including diabetes, idiopathic pulmonary fibrosis (IPF), and primary biliary cholangitis (PBC).


  • NADPH oxidase 4 contributes to TRPV4-mediated endothelium-dependent vasodilation in human arterioles by regulating protein phosphorylation of TRPV4 channels

    by Yangjing Xie, Yoshinori Nishijima, Natalya S. Zinkevich, Ankush Korishettar, Juan Fang, Angela J. Mathison, Michael T. Zimmermann, David A. Wilcox, David D. Gutterman, Yuxian Shen, et al.

    Impaired endothelium-dependent vasodilation has been suggested to be a key component of coronary microvascular dysfunction (CMD). A better understanding of endothelial pathways involved in vasodilation in human arterioles may provide new insight into the mechanisms of CMD. The goal of this study is to investigate the role of TRPV4, NOX4, and their interaction in human arterioles and examine the underlying mechanisms. Arterioles were freshly isolated from adipose and heart tissues obtained from 71 patients without coronary artery disease, and vascular reactivity was studied by videomicroscopy. In human adipose arterioles (HAA), ACh-induced dilation was significantly reduced by TRPV4 inhibitor HC067047 and by NOX 1/4 inhibitor GKT137831, but GKT137831 did not further affect the dilation in the presence of TRPV4 inhibitors. GKT137831 also inhibited TRPV4 agonist GSK1016790A-induced dilation in HAA and human coronary arterioles (HCA). NOX4 transcripts and proteins were detected in endothelial cells of HAA and HCA. Using fura-2 imaging, GKT137831 significantly reduced GSK1016790A-induced Ca2+ influx in the primary culture of endothelial cells and TRPV4-WT-overexpressing human coronary artery endothelial cells (HCAEC). However, GKT137831 did not affect TRPV4-mediated Ca2+ influx in non-phosphorylatable TRPV4-S823A/S824A-overexpressing HCAEC. In addition, treatment of HCAEC with GKT137831 decreased the phosphorylation level of Ser824 in TRPV4. Finally, proximity ligation assay (PLA) revealed co-localization of NOX4 and TRPV4 proteins. In conclusion, both TRPV4 and NOX4 contribute to ACh-induced dilation in human arterioles from patients without coronary artery disease. NOX4 increases TRPV4 phosphorylation in endothelial cells, which in turn enhances TRPV4-mediated Ca2+ entry and subsequent endothelium-dependent dilation in human arterioles.


  • Open Access

    Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2

    by Yoshinori Nishijima, Shelby N Hader, Alena J Hanson, David X Zhang, Rodney Sparapani, David D Gutterman, Andreas M Beyer

    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has a major global impact and is responsible for over 230 million cases and 4.7 million deaths worldwide. 1


  • Endothelial Rap1 (Ras-Association Proximate 1) Restricts Inflammatory Signaling to Protect From the Progression of Atherosclerosis

    by Bandana Singh, Ramoji Kosuru, Sribalaji Lakshmikanthan, Mary G. Sorci-Thomas, David X. Zhang, Rodney Sparapani, Jeannette Vasquez-Vivar, Magdalena Chrzanowska

    Objective: Small GTPase Rap1 (Ras-association proximate 1) is a novel, positive regulator of NO release and endothelial function with a potentially key role in mechanosensing of atheroprotective, laminar flow. Our objective was to delineate the role of Rap1 in the progression of atherosclerosis and its specific functions in the presence and absence of laminar flow, to better define its role in endothelial mechanisms contributing to plaque formation and atherogenesis. Approach and Results: In a mouse atherosclerosis model, endothelial Rap1B deletion exacerbates atherosclerotic plaque formation. In the thoracic aorta, where laminar shear stress–induced NO is otherwise atheroprotective, plaque area is increased in Athero-Rap1B iΔEC (atherogenic endothelial cell–specific, tamoxifen-inducible Rap1A+Rap1B knockout) mice. Endothelial Rap1 deficiency also leads to increased plaque size, leukocyte accumulation, and increased CAM (cell adhesion molecule) expression in atheroprone areas, whereas vascular permeability is unchanged. In endothelial cells, in the absence of protective laminar flow, Rap1 deficiency leads to an increased proinflammatory TNF-α (tumor necrosis factor alpha) signaling and increased NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation and elevated inflammatory receptor expression. Interestingly, this increased signaling to NF-κB activation is corrected by AKTVIII—an inhibitor of Akt (protein kinase B) translocation to the membrane. Together, these data implicate Rap1 in restricting Akt-dependent signaling, preventing excessive cytokine receptor signaling and proinflammatory NF-κB activation. Conclusions: Via 2 distinct mechanisms, endothelial Rap1 protects from the atherosclerosis progression in the presence and absence of laminar flow; Rap1-stimulated NO release predominates in laminar flow, and restriction of proinflammatory signaling predominates in the absence of laminar flow. Our studies provide novel insights into the mechanisms underlying endothelial homeostasis and reveal the importance of Rap1 signaling in cardiovascular disease.